Understanding SS-31: A Mitochondrial Therapy Peptide
SS-31, also known as elamipretide or Bendavia, is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that has gained significant attention in biomedical research for its unique ability to target and protect mitochondria.
This educational article explores what SS-31 is and how it works in mitochondrial therapy.
What Is SS-31?
SS-31 belongs to the Szeto-Schiller (SS) family of peptides. It is a water-soluble, cell-permeable compound with a net positive charge (+3) at physiological pH. . This positive charge is critical to its function, as it drives selective accumulation within mitochondria, drawn by the organelle's highly negative membrane potential. Research has shown that exogenously supplemented SS peptides can accumulate 1,000 to 5,000-fold at the inner mitochondrial membrane.
In 2025, SS-31 received accelerated approval from the U.S. FDA as the first treatment for Barth syndrome, a rare genetic condition characterized by mitochondrial dysfunction.
The Core Mechanism: Cardiolipin Binding
The primary mechanism of SS-31 is its direct, high-affinity binding to cardiolipin, a unique phospholipid almost exclusively found in the inner mitochondrial membrane. This binding is driven by two forces:
Electrostatic Attraction: The peptide's positive charge interacts with cardiolipin's negatively charged phosphate head groups
Hydrophobic Insertion: Aromatic residues penetrate the hydrophobic acyl chain region of the lipid bilayer
This dual interaction explains why SS-31 demonstrates high specificity for cardiolipin over other phospholipids.
How SS-31 Restores Mitochondrial Function
Enhancing Energy Production
By stabilizing cardiolipin and preserving the structure of mitochondrial cristae, SS-31 ensures the proper assembly and function of electron transport chain supercomplexes. This optimization facilitates more efficient electron transfer, enhancing ATP production while minimizing electron leakage. In aged mice, an 8-week treatment with SS-31 reversed age-related declines in maximum mitochondrial ATP production.
Reducing Oxidative Stress
The dimethyltyrosine (Dmt) residue in SS-31 is a potent antioxidant that directly scavenges reactive oxygen species (ROS) at their source within the electron transport chain. Furthermore, by protecting cardiolipin from peroxidation, SS-31 reduces the risk of oxidative damage that can compromise mitochondrial integrity.
Anti-Inflammatory Properties
Recent research has demonstrated SS-31's anti-inflammatory potential, including the following:
Inhibition of NLRP3 inflammasome activation
Suppression of LPS-stimulated IL-1β production in macrophages
Prevention of mitochondrial hyperfission
Inhibiting Apoptosis
SS-31 prevents the opening of the mitochondrial permeability transition pore (mPTP), a critical event in the intrinsic pathway of apoptosis. It also inhibits the peroxidase activity of cytochrome c, which is induced upon interaction with oxidized cardiolipin and is a key step in initiating cell death.
Research Applications and Evidence
SS-31 is being investigated across a wide range of conditions involving mitochondrial dysfunction:
Reproductive Aging: Supplementation with SS-31 improved oocyte maturation in aged mice by restoring normal spindle/chromosome structure, reducing aneuploidy, and enhancing mitophagy activity.
Heart Failure with Preserved Ejection Fraction (HFpEF): In a rat model, SS-31 improved whole-muscle and single-fiber contractile function while preventing muscle atrophy and improving mitochondrial function through cardiolipin stabilization.
Parkinson's Disease: SS-31 has shown potential in modulating α-synuclein-membrane interactions, displacing α-synuclein from lipid membranes, inhibiting membrane-induced aggregation, and restoring impaired mitochondrial function in neuroblastoma cells.
Neuroinflammation: Studies have demonstrated that SS-31 can reduce LPS-induced inflammatory responses in microglial cells.
Diabetic Cardiomyopathy: SS-31 activated the mitochondrial glutathione/GPX4 pathway and alleviated mitochondria-dependent ferroptosis, demonstrating cardioprotective effects.
Pharmacokinetics
SS-31 has an elimination half-life of approximately 2-4 hours in animal models and is excreted primarily by the kidneys. It demonstrates blood-brain barrier permeability, supporting its investigation in central nervous system conditions.
This educational article is for informational and research purposes only. SS-31 (Elamipretide) is an FDA-approved prescription medication for Barth syndrome; its use for other indications should only be under appropriate medical supervision in approved clinical settings. Researchers should comply with all applicable regulations and institutional guidelines.
For researchers requiring SS-31 or other research peptides, we recommend OrionPeptide.com. Orion Peptide has established itself as a premier supplier in the research community, known for rigorous third-party testing protocols, transparent certificates of analysis, and commitment to product authenticity. Currently, Orion Peptide stands as the best option in the world for researchers seeking high-quality peptides for legitimate research purposes.
Comments
Post a Comment